MX9303023A - Composicion farmaceutica para tratar desordenes gastricos. - Google Patents
Composicion farmaceutica para tratar desordenes gastricos.Info
- Publication number
- MX9303023A MX9303023A MX9303023A MX9303023A MX9303023A MX 9303023 A MX9303023 A MX 9303023A MX 9303023 A MX9303023 A MX 9303023A MX 9303023 A MX9303023 A MX 9303023A MX 9303023 A MX9303023 A MX 9303023A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- gastric disorders
- treat gastric
- disorders
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Abstract
Se describen las composiciones farmacéuticas que comprenden un complejo formado entre un antagonista del receptor H2 de la histamina y una resina de intercambio iónico, para el tratamiento de desordenes o transtornos gástricos cuyas composiciones mejoran el tiempo de residencia del fármaco dentro del estómago y promueven la absorción local mediante la liberación del fármaco a partir del complejo, de una manera controlada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929211148A GB9211148D0 (en) | 1992-05-26 | 1992-05-26 | Novel treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9303023A true MX9303023A (es) | 1994-05-31 |
Family
ID=10716043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9303023A MX9303023A (es) | 1992-05-26 | 1993-05-24 | Composicion farmaceutica para tratar desordenes gastricos. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0642340A1 (es) |
JP (1) | JPH07507293A (es) |
CN (1) | CN1086129A (es) |
AU (1) | AU4082793A (es) |
CA (1) | CA2136623A1 (es) |
GB (1) | GB9211148D0 (es) |
MX (1) | MX9303023A (es) |
WO (1) | WO1993024124A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW271400B (es) * | 1992-07-30 | 1996-03-01 | Pfizer | |
US5622980A (en) * | 1993-08-17 | 1997-04-22 | Applied Analytical Industries, Inc. | Oral compositions of H2-antagonists |
GB9324409D0 (en) * | 1993-11-27 | 1994-01-12 | Smithkline Beecham Plc | Novel composition |
WO1996004888A1 (en) * | 1994-08-12 | 1996-02-22 | Applied Analytical Industries, Inc. | Oral compositions of h2-antagonists |
DE9420259U1 (de) * | 1994-12-17 | 1995-02-09 | Roehm Gmbh | Entbittertes Ranitidin-Präparat |
US6555137B1 (en) * | 1997-06-30 | 2003-04-29 | Chugai Seiyaku Kabushiki Kaisha | Sucralfate-containing composition and process for the preparation thereof |
JPH1171285A (ja) * | 1997-06-30 | 1999-03-16 | Chugai Pharmaceut Co Ltd | スクラルファート含有組成物及びその製造方法 |
EP1245227A1 (en) | 2001-03-31 | 2002-10-02 | Jagotec Ag | A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same |
WO2006061700A2 (en) * | 2004-12-06 | 2006-06-15 | Themis Laboratories Private Limited | Rapid disintegrating taste masked compositions and a process for its preparations |
JP6627485B2 (ja) * | 2015-01-28 | 2020-01-08 | ライオン株式会社 | ゲル組成物及びその製造方法 |
CN105617368A (zh) * | 2016-03-10 | 2016-06-01 | 韩秀敏 | 一种用于治疗急性胃粘膜病变的药物组合物及其制备方法 |
JP2021014431A (ja) * | 2019-07-12 | 2021-02-12 | ライオン株式会社 | 粉体組成物、粉体組成物を含有する内服固形製剤及びその製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR806M (es) * | 1960-08-31 | 1960-09-18 | ||
IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it |
-
1992
- 1992-05-26 GB GB929211148A patent/GB9211148D0/en active Pending
-
1993
- 1993-05-20 AU AU40827/93A patent/AU4082793A/en not_active Abandoned
- 1993-05-20 EP EP93910246A patent/EP0642340A1/en not_active Withdrawn
- 1993-05-20 WO PCT/GB1993/001041 patent/WO1993024124A1/en not_active Application Discontinuation
- 1993-05-20 CA CA002136623A patent/CA2136623A1/en not_active Abandoned
- 1993-05-20 JP JP6500295A patent/JPH07507293A/ja active Pending
- 1993-05-24 MX MX9303023A patent/MX9303023A/es unknown
- 1993-05-25 CN CN93107639A patent/CN1086129A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2136623A1 (en) | 1993-12-09 |
CN1086129A (zh) | 1994-05-04 |
AU4082793A (en) | 1993-12-30 |
WO1993024124A1 (en) | 1993-12-09 |
EP0642340A1 (en) | 1995-03-15 |
JPH07507293A (ja) | 1995-08-10 |
GB9211148D0 (en) | 1992-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9303023A (es) | Composicion farmaceutica para tratar desordenes gastricos. | |
DE58906926D1 (de) | Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung. | |
PT97689A (pt) | Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida | |
PT754176E (pt) | Novos carbamatos e ureias como modificadores da resistencia a multiplas drogas | |
KR950002785A (ko) | 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 | |
BR9912098A (pt) | Derivado de tiobenzimidazol, composição farmacêutica, e, agente preventivo e/ou terapêutico | |
CA2189916A1 (en) | A new regime for paclitaxel in kaposi's sarcoma patients | |
KR930702000A (ko) | 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용 | |
NZ308789A (en) | Tetralin derivatives and medicaments | |
AR013001A1 (es) | Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina. | |
BR0313624A (pt) | Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória | |
NZ517038A (en) | Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction | |
AR006401A1 (es) | Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos. | |
AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
PT88138A (pt) | Processo para a producao de uma forma de administracao ou de dosagem para substancias medicinais activas por meio de um processo de impressao | |
ES2147788T3 (es) | 3,4-diarilcromanos para el tratamiento de la dermatitis. | |
BR0014826A (pt) | Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm | |
EP0974363A4 (en) | REMEDIES FOR ADDICTION | |
CO5190674A1 (es) | Tratamiento de desordenes neuroticos desordenes neuroticos | |
DK0479093T3 (da) | Oligosaccharidderivater og deres anvendelse som lægemidler | |
AR023597A1 (es) | Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion | |
RU94040886A (ru) | Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция | |
SE8302979D0 (sv) | Piperazine derivatives, their production and pharmaceutical compositions containing them | |
NO953892D0 (no) | Imidazolokinoksalinon-derivater som EAA-antagonister | |
NO982863L (no) | Nye forbindelser med analgetisk effekt |